Findings in mice reveal possibilities for fetal drug therapy for deafness
6 April 2020

New research led by hearing scientists at Oregon Health & Science University suggests an avenue to treat and prevent intractable genetic disorders before birth.

Researchers at the Oregon Hearing Research Center, working with mice, injected a specially designed synthetic molecule into the developing inner ear of fetal mice 12 days after fertilization. The study found that the technique corrected the expression of a mutated gene that causes Usher syndrome, a disorder characterized by deafness and progressive vision loss affecting an estimated 4 to 17 of every 100,000 people.

"This shows that direct administration of the ASO to the inner ear restored hearing and balance," said senior author John V. Brigande, Ph.D., principle investigator for the Oregon Hearing Research Center at OHSU.

Scientists designed a synthetic antisense oligonucleotide, or ASO, which targets and then attaches to precise nucleic acid sequences. In this case, the molecule was designed to target pre-messenger RNA, a class of molecules that influences when, where, and how strongly genes are expressed in a cell. When scientists injected the ASO into the developing inner ear of fetal mice carrying the gene mutation, the mice developed with no symptoms of Usher syndrome.

"This work represents the latest in several OHSU initiatives to develop new genetic tools to address genetic conditions.

Recently, researchers in the OHSU Casey Eye Institute for the first time used another gene editing technique called CRISPR to edit genes within the human body. In 2017, OHSU researchers generated worldwide attention when they corrected a gene mutation that causes a deadly heart condition in early human embryos.

"In our complementary approach to gene editing in early-stage embryos in a dish, we seek to correct aberrant gene expression in the fetal inner ear while inside the uterus to restore hearing and balance," Brigande said. "We think both approaches have high merit."

More information: Lingyan Wang et al, Fetal antisense oligonucleotide therapy for congenital

Researchers expect to move from a mouse model to nonhuman primates, which more closely model human hearing loss, before the technique would be ready for human clinical trials. Brigande said he expects it will be useful in potentially treating and preventing several types of congenital forms of hearing and balance disorders.

The findings will be published in the journal Nucleic Acids Research.

Provided by Oregon Health & Science University

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.